secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0000950170-25-068020
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma Q1 net loss narrows to $9.1M; ATH-1105 Phase 1 complete, ALS dosing on track
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments totaled $36.7M as of March 31, 2025, down from $51.3M at year-end 2024.
- Net loss for Q1 2025 was $9.1M ($0.23 per share) vs $26.3M ($0.69 per share) in Q1 2024.
- R&D expenses fell to $4.3M from $21.2M, driven by fosgonimeton program cuts after failed LIFT-AD trial.
- ATH-1105 Phase 1 healthy volunteer study completed; full data expected 2H25, ALS patient dosing to begin late 2025.
- Company exploring strategic alternatives with Cantor Fitzgerald after discontinuing fosgonimeton development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017025068020/0000950170-25-068020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017025068020/atha-20250509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-068020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer